powered by StockChartsAI.com

All Charts and Prices Based on Previous Days Close

Enter Stock Symbol to View AI powered Stock Chart

By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.

Ultragenyx (RARE)

Industry: Biotechnology

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Ultragenyx Pharmaceutical Inc Website


Institution %: 98.579

YTD Institution change: 3198907


Insiders %: 4.665

Insiders Purchases YTD:

Insiders Sales YTD: 112569

Insiders Net YTD: -112569

Analyst Ratings

Target Price: 90.56

Overall Rating: 4.5263

Strong Buys (5): 12

Buys (4): 5

Holds (3): 2

Sells (2): 0

Strong Sells (1): 0


52 Week Hi: 54.98

52 Week Low: 31.52

Beta: 0.719

50 Day MA: 36.0444

200 Day MA: 41.2939

Earnings / Revenue Trends

Qtr Earnings Growth YOY: 0

Qtr Revenue Growth YOY: 0.081

Forward PE:

Trailing PE: